These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 32285358)

  • 1. Ruxolitinib as first-line therapy in secondary hemophagocytic lymphohistiocytosis and HIV infection.
    Gálvez Acosta S; Javalera Rincón M
    Int J Hematol; 2020 Sep; 112(3):418-421. PubMed ID: 32285358
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of the JAK Inhibitor Ruxolitinib in the Treatment of Hemophagocytic Lymphohistiocytosis.
    Keenan C; Nichols KE; Albeituni S
    Front Immunol; 2021; 12():614704. PubMed ID: 33664745
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Case report: Ruxolitinib as first-line therapy for secondary hemophagocytic lymphohistiocytosis in patients with AIDS.
    Liu X; Zhu X; Zhou X; Xie Y; Xiang D; Wan Z; Huang Y; Zhu B
    Front Immunol; 2022; 13():1012643. PubMed ID: 36263041
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined Use of Emapalumab With Ruxolitinib and Dexamethasone as an Effective Treatment for Epstein-Barr Virus-associated Hemophagocytic Lymphohistiocytosis Complicated With Multiorgan Damage and Severe Infection.
    Liang J; Xu X; Chen Z; Yu J; Tang Y
    J Pediatr Hematol Oncol; 2024 Jul; 46(5):e360-e362. PubMed ID: 38691058
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Falciparum malaria-induced secondary hemophagocytic lymphohistiocytosis successfully treated with ruxolitinib.
    Fuchs A; Orth HM; Germing U; Kondakci M; Holtfreter M; Feldt T; Jensen BE; Häussinger D
    Int J Infect Dis; 2020 Nov; 100():382-385. PubMed ID: 32777582
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ruxolitinib for secondary hemophagocytic lymphohistiocytosis: First case report.
    Sin JH; Zangardi ML
    Hematol Oncol Stem Cell Ther; 2019 Sep; 12(3):166-170. PubMed ID: 28834694
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ruxolitinib for the treatment of lymphoma-associated hemophagocytic lymphohistiocytosis: A cautionary tale.
    Trantham T; Auten J; Muluneh B; Van Deventer H
    J Oncol Pharm Pract; 2020 Jun; 26(4):1005-1008. PubMed ID: 31575356
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A pilot study of ruxolitinib as a front-line therapy for 12 children with secondary hemophagocytic lymphohistiocytosis.
    Zhang Q; Wei A; Ma HH; Zhang L; Lian HY; Wang D; Zhao YZ; Cui L; Li WJ; Yang Y; Wang TY; Li ZG; Zhang R
    Haematologica; 2021 Jul; 106(7):1892-1901. PubMed ID: 32732367
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Short-term effectiveness of ruxolitinib in the treatment of recurrent or refractory hemophagocytic lymphohistiocytosis in children.
    Wei A; Ma H; Li Z; Zhang L; Zhang Q; Wang D; Lian H; Zhang R; Wang T
    Int J Hematol; 2020 Oct; 112(4):568-576. PubMed ID: 32666469
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ruxolitinib as adjunctive therapy for secondary hemophagocytic lymphohistiocytosis: A case series.
    Hansen S; Alduaij W; Biggs CM; Belga S; Luecke K; Merkeley H; Chen LYC
    Eur J Haematol; 2021 May; 106(5):654-661. PubMed ID: 33523540
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ruxolitinib in adult patients with secondary haemophagocytic lymphohistiocytosis: an open-label, single-centre, pilot trial.
    Ahmed A; Merrill SA; Alsawah F; Bockenstedt P; Campagnaro E; Devata S; Gitlin SD; Kaminski M; Cusick A; Phillips T; Sood S; Talpaz M; Quiery A; Boonstra PS; Wilcox RA
    Lancet Haematol; 2019 Dec; 6(12):e630-e637. PubMed ID: 31537486
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful treatment of cytomegalovirus-induced hemophagocytic lymphohistiocytosis with ruxolitinib as a first-line treatment.
    Meng G; Wang J; Wang Y; Wang Z
    Infect Dis Now; 2021 May; 51(3):311-313. PubMed ID: 33934812
    [No Abstract]   [Full Text] [Related]  

  • 13. Ruxolitinib is an alternative to etoposide for patient with hemophagocytic lymphohistiocytosis complicated by acute renal injury: A case report.
    Yan WL; Yang SL; Zhao FY; Xu XJ
    J Oncol Pharm Pract; 2022 Jan; 28(1):222-227. PubMed ID: 34074166
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ruxolitinib for hematopoietic cell transplantation-associated hemophagocytic lymphohistiocytosis.
    Ono R; Ashiarai M; Hirabayashi S; Mizuki K; Hosoya Y; Yoshihara H; Ohtake J; Mori S; Manabe A; Hasegawa D
    Int J Hematol; 2021 Feb; 113(2):297-301. PubMed ID: 32979171
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Ruxolitinib as an effective treatment for panniculitis associated hemophagocytic syndrome: A report of 2 cases and literature review].
    Li GM; Jin YB; Gan YZ; Chen C; Jia Y; Li C
    Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Dec; 54(6):1208-1213. PubMed ID: 36533357
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Etoposide combined with ruxolitinib for refractory hemophagocytic lymphohistiocytosis during pregnancy: a case report and literature review.
    Wang S; Wu J; Jing X; Zhang Y; Tang H; Wu J
    Hematology; 2019 Dec; 24(1):751-756. PubMed ID: 33138732
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ruxolitinib as first-line treatment in secondary hemophagocytic lymphohistiocytosis: A single patient experience.
    Slostad J; Hoversten P; Haddox CL; Cisak K; Paludo J; Tefferi A
    Am J Hematol; 2018 Feb; 93(2):E47-E49. PubMed ID: 29134683
    [No Abstract]   [Full Text] [Related]  

  • 18. Ruxolitinib in Alleviating the Cytokine Storm of Hemophagocytic Lymphohistiocytosis.
    Jianguo L; Zhixuan Z; Rong L; Xiaodong S
    Pediatrics; 2020 Aug; 146(2):. PubMed ID: 32680878
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Etiologies and Clinical Outcomes of Patients With Secondary Hemophagocytic Lymphohistiocytosis at a Tertiary PICU.
    Dao D; Xoay TD; Galeano BK; Phuc PH; Ouellette Y
    Pediatr Crit Care Med; 2019 Jul; 20(7):e311-e318. PubMed ID: 31149968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fulminant hemophagocytic lymphohistiocytosis secondary to a reactivated EBV infection: a case report.
    Antonodimitrakis P; Wassberg C; Gerovasileiou S; Back J; Hällgren R; Olsen B
    Ups J Med Sci; 2013 Mar; 118(1):42-5. PubMed ID: 23398237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.